Avicine, tested and developed by AVI BioPharma, and also known as CTP-37 was trialled as a possible cancer vaccine to treat a number of different cancers.[1] These included colorectal cancer, pancreatic cancer and prostate cancer.[1] The treatment was trialled as and intended to be induced via intramuscular injection[1] into the bloodstream, the location dependent on the treatment area.[2]
Common side effects during clinical trials included fever and chills as experienced with many other conventional vaccines.[1] The vaccine operated by eliciting antibodies against human chorionic gonadotropin (hCG) a cancer associated protein expressed by most cancer cells, with the goal of prolonged survival for those affected.[3]
Avicine was originated by AVI BioPharma in the USA,[3] who licensed the product to SuperGen.[4] However, due to delays in clinical testing, as a result of research difficulties, the owners of Avicine were forced to direct their attention to other areas being the investigation and treatment of cardiovascular and infectious disease indications.[1][4]